Our technology was discovered studying human tumors and the evidencing data are mainly from human studies, providing a clear indication for success in humans. The therapy is effected with immune hormones that are proteins already present in the human body and thus not toxic. The treatment is regenerative for patients and can be administered to advance stage patients and treat multiple tumor sites simultaneously. The treatment time is short spanned (1 month) and promotes self healing in lieu of a year of toxic radiotherapy or chemotherapy. Most effectively, it offers long-term protection against relapses by generating self-vaccination against the regressed tumor.